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Second messengerThe general structure of the P2X7 receptor (P2X7R) is similar to the structure of other P2X receptor family
members, with the exception of its C terminus, which is the longest of this family. The P2X7R activates several
intracellular signaling cascades, such as the calmodulin, mitogen-activated protein kinase and phospholipase
D pathways. At low concentrations of ATP (micromolar range), P2X7R activation opens a cationic channel, sim-
ilarly to other P2X receptors. However, in the presence of high concentrations of ATP (millimolar range), it opens
a pathway that allows the passage of larger organic cations and anions. Here, we discuss both the structural char-
acteristics of P2X7R related to its remarkable functions and the proposed mechanisms, including the dilation of
the endogenous pore and the integration of another channel. In addition, we highlight the importance of
P2X7R as a therapeutic target.
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The initial concept of purinergic extracellular actions was developed
in the 1920s based on experiments using the cardiovascular system that
demonstrated the effects of crude tissue extracts. The principal active
compound in these extracts was identiﬁed to be adenosine-5′-
monophosphate [1]. A study conducted in 1965 described the effects
of caffeine on guinea pig atria and clearly demonstrated that adenosinereceptors are inhibited by this alkaloid [2]. Nevertheless, more than half
a century passed before purines were formally proposed as signaling
molecules. Purinergic neurotransmission was formally proposed in a
classical paper published in Pharmacological Review that described the
identiﬁcation of adenosine 5′-triphosphate (ATP) as the signalmolecule
in non-adrenergic, non-cholinergic inhibitory nerves in guinea pigs [3].
Three subclasses of purine and pyrimidine receptors have been identi-
ﬁed to date: P1 adenosine receptors (A1, A2a, A2b and A3) and the P2
family, which is further divided into ionotropic (P2X) andmetabotropic
receptors (P2Y). The ionotropic P2X receptor subfamily is composed of
2579L.A. Alves et al. / Biochimica et Biophysica Acta 1838 (2014) 2578–2587ATP-gated ion channels and includes seven members (P2X1–7), while
the P2Y G protein-coupled receptor (GPCR) subfamily contains eight
subtypes (P2Y1, 2, 4, 6, 11, 12, 13 and 14) [4,5].
2. Overview of P2X receptors
The P2X family is composed of the excitatory ATP-gated P2X receptors
(P2XRs). Seven genes (P2XR1–7) encode the seven P2XR subunits (P2X1–
7) that are found inmultiple species fromunicellular organisms tohumans
[6]. However, prokaryotic P2XRs have not been reported [7]. The majority
of P2XR subtypes are non-selective cation channels with high Ca2+ per-
meability. The exception is the P2X5Rs, which are permeable to Cl− [8].
These receptors play important roles in cell–cell communication
throughmodulating synaptic transmission, contracting smoothmuscle,
regulating immune responses, inducing rapid conformational changes
in gates and triggering transmembrane ﬂuxes of selective ions [7,9–11].
P2XR channels are composed of three subunits that assemble either
as homo- or heterotrimeric complexes. Each subunit contains two
transmembrane domains, including a large cysteine-rich extracellular
domain (~280 residues) and intracellular C- and N-termini [18–21].
These subunits present a relatively simple architecture among ligand-
gated ion channels (LGICs), in contrast to the tetrameric eukaryotic
glutamate receptors (GluRs) [12] or the pentameric receptors of the
Cys-loop family [13]. The trimeric purinergic structure more closely
resembles epithelial Na+ channels (ENaC), including the recently
described acid-sensing ion channels (ASICs) [14,15].
The second transmembrane domain (TM2) is a key structure in
P2XR channel formation, although TM1 also plays a role in the integral
function of these receptors [16]. Mutations in this domain cause minor
changes in ATP-gated currents. In agreement with these ﬁndings,
zebraﬁsh P2X4 (zfP2X4) crystal structure models have shown that
TM2 lines the ion pathway, while TM1 is positioned peripherally
[17–24].
In general, the gating of P2XRs consists of three phases: a rapid
phase involving an inward current induced by the application of an ag-
onist (activation phase); a slow decay phase in the presence of the ago-
nist (desensitization phase); and a rapid decay of the current following
ATP depletion (deactivation phase). Themain differences among P2XRs
lie in their sensitivity to agonists and their desensitization rates [7,9].
Although all P2XRs open a cationic channel within milliseconds
when activated by their native agonist, some channels (the P2X2R,
P2X4R and P2X7R channels) provide not only a narrow conducting
pathway that allows the passage of small ions but also a pathway for
the passage of larger organic cations. The pore formation of P2X7R is
prototypical for these channels. The mechanism by which this forma-
tion occurs is still unknown, but it may involve the dilation of the en-
dogenous pore or via the participation of another channel through the
activation of second messenger cascades [6,25–27].
3. Structural aspects of the P2X7R
Because the focus of the present review is the P2X7R,wewill use the
available evidence to provide further details about the structural charac-
teristics of this receptor. Different structural features are observed
among the P2XRs, and consequently, these proteins have different func-
tional behaviors. Comparedwith other P2XR subtypes, P2X7R requires a
high concentration of ATP (N100 μM) to evoke a current, and upon acti-
vation by an agonist, it opens a high-conductance pore that allows the
passage of high-molecular-weight molecules across the plasma mem-
brane [28,29]. The processes by which this receptor undergoes this
striking behavior remain unknown, and it is the most inexplicable phe-
nomenon faced in P2X physiology (see hypothesis below).
There have been few studies addressing the structural binding site of
P2X7R. However, the site appears to involve the same conserved lysine
residues in the extracellular loop that are important for other P2Xmem-
ber subtypes. The conserved lysines have been proposed to interactwith negatively charged phosphate groups because these residues
have been shown to interact with ATP molecules in the P2X1 [29,30]
and P2X2 [31] subtypes. The conserved lysine residues have also been
found to interact with ATP in a crystal structure model of the P2X4 re-
ceptor [24]. Furthermore, the K193A and K311Amutations (P2X7 num-
bering) have been shown to impair P2X7 function; therefore, these
residues could be directly involved in the binding of ATP to this site
[32]. These data are consistent with the homologous residues found in
the P2X1, P2X2 and P2X4 receptors [29,31,33–36]. Moreover, aromatic
residues are necessary for interactions with the adenine base, which
have been observed in other ATP-binding proteins [37], and these inter-
actions confer base speciﬁcity. It has been hypothesized that this pattern
also occurs in the P2X7R subtype, but further studies are needed to test
this proposal.
One of themost intriguing domains of P2X7R is its C terminus (for a
complete review of this topic, see Costa-Junior et al. [38]). P2X7R ex-
hibits the longest C terminus of the P2X subtypes and bears structural
motifs that suggest that it serves as a docking site for intracellular pro-
tein interactions [39]. Moreover, a lipopolysaccharide (LPS)-binding
motif has been reported in P2X7R that might serve as a modulator of
its function and could explain the role of P2X7R in response to intracel-
lular pathogens [40]. In this context, it has been shown that pointmuta-
tions in the C terminus can alter or abolish the function of P2X7R [41].
Similar to the other P2X subtypes, the second transmembrane domain
of P2X7R appears to line the ion pathway across themembrane [42]. Data
onother ion channels showthat the selectivity characteristics of a channel
can be altered via changes in the residues in the ion permeation pathway
or in adjacent regions, as demonstrated for P2X2R [43], 5-HT(3a)R [44]
and nicotinic AchR [45]. Recent data show that mutations in the second
transmembrane domain of P2X7R alter its selectivity properties [42].
For example, the mutations T348K, D352N and D352K cause mutant re-
ceptors to become more permeable to anions, revealing the importance
of these residues for ion selectivity. Moreover, in that same study, the au-
thors used cysteine-accessibility scans to determine the accessibility of
residues G345 and T348, both of which are likely to be located along the
ion permeation pathway. When biotin-linked methanethiosulfonate
ethylammonium (MTSEA), a methyl thiosulfonate reagent with molecu-
lar dimensions of 0.75 × 0.80 × 1.85 nm, was used in these assays, the
ATP-evoked currents were diminished only when the cells were treated
with ATP prior to treatment with biotin-linked MTSEA. This ﬁnding re-
veals that the dimensions of the ion permeation pathway at these residue
positions when the receptor is activated are greater than the dimensions
of biotin-linked MTSEA.
Asmentioned previously, P2X7R shows two distinct functions: a low-
conductance channel that allows the passage of small ions across the
membrane and a high-conductance channel (large-pore channel) that
allows the uptake of high-molecular-weight dyes. However, the mecha-
nism underlying the second state remains unknown. The literature pre-
sents two hypotheses to explain how P2X7R shifts from a low- to a
high-conductance state: In the ﬁrst hypothesis, the channel formed by
P2X7R is gradually opened upon activation; thus, increasing its conduc-
tance from ions to large molecules (up to 900 Da in macrophages), it
can pass rather than just ions or small molecules, i.e., the pore dilates
[46,47]. In the second hypothesis, the P2X7R (high-conductance state)
is formedupon activation through the involvement of secondmessengers
that may activate an independent pore-forming membrane protein [25,
27]. Evidence for both of these hypotheses is found in the literature, as il-
lustrated in Table 1. These proposalswill be discussed in the next sections.
4. P2X7R as an intriguing ion channel
In 1967, Diamant and Kruger [48] were the ﬁrst investigators to
clearly demonstrate the extracellular actions of ATP in mast cells,
where it triggers histamine release. The receptor activated by ATP was
formally deﬁned by Cockcroft and Gomperts [49] and designated P2Z
by Soltoff [50].
Table 1
Hypothesis for the mechanism of the pore activation associated with P2X7R.
Cell type (P2X7R species) Technique approaches Reference Results
Dilation hypothesis
NTW8 mouse microglial (mouse) Patch-clamp [74] 1 mM ATP application reached a plateau — 300% increase over the current
magnitude.
HEK-293 (rat) Patch-clamp [54] The authors conclude that the maximum receptor activation causes an
exponential dilation of the ion channel with a time constant of 25 s from an
initial diameter of 0.8 nm to a ﬁnal pore diameter of 3–5 nm.
HEK-293 (mouse, human and rat) Large weight dye uptake and confocal imaging [56] Repeated 100 μM BzATP applications within 10 to 30 s stimulated increase in
YO-PRO-1 accumulation suggesting a pore dilation.
THP-1 and HEK-293 (human) Patch-clamp [75] ATP application promotes the dissociation of P2X7 from nonmuscle myosin in
both cell types leading to large pore formation.
Hippocampal neuron–glia (rat) Dye uptake and confocal imaging [76] BzATP application leads to cation channel function but it impairs the pore
formations activity in mutant P2X7R (G345Y). It implicates that changes
whithin P2X7R could alters directly the or formatin activity.
HEK-293 (rat) Patch-clamp [47] After sustained application (40 s) of 100 μM BzATP the pore dilates reaching
the permeability for organic cations independent of pannexin
pharmacological block.
HEK-293 (human) Patch-clamp [60] The authors developed a mathematical model suggesting that two agonist
binding site occupancies lead to the channel activity while 3 occupied binding
sites lead to the pore formation.
HEK-293 and GT1 (rat) Patch-clamp [77] The authors also used a mathematical model that suggests that the number of
agonist binding site occupancy determines the ion channel or pore function of
P2X7 receptor as the same molecular entity.
HEK-293 (human) Patch-clamp, cysteine accessibility anddyeuptake [42] Some residues predicted to be in second transmembrane domain are
accessible to large diameter methanosulfonate reagents and diminished the
P2X7 dependent dye uptake
“Other protein” hypothesis
Xenopus oocytes (rat) Patch-clamp [78] Heterologously expressed P2X7 receptor did not produce pore forming activity.
HEK-293 (human) Patch-clamp and dye uptake [79] C-terminal truncated P2X7 variant (P2X7B) fails to trigger membrane per-
meabilization although it keeps ATP-induced channel activity. It could suggest
that some protein linked to C-terminal may be essential to non-selective pore
formation.
Peritoneal macrophages (mouse) Patch-clamp [25,27] Cationic channel and pore opening in the same patch in cell-attached and
outside out approaches were not observed.
J774 (mouse), THP-1 (human) and
HEK-293 (human)
Patch-clamp, and dye uptake assay [81] ATP induced dye uptake (not the ion channel activity) was inhibited in the
absence or by the pharmacological block of pannexin. Pannexin co-
immunoprecipitates with heterologously expressed P2X7.
2BH4 (mouse) Dye uptake [80] In cell attached conﬁguration, when ATP is applied in the bath, it may induce
pore formation in the patch.
HEK-293 (mouse) and RAW 264.7
(mouse)
Dye uptake [66] The authors showed that there are two putative dye uptake pathways
occurring in heterologously or naturally expressed P2X7 receptor. Negatively
charged dyes were uptaken in a Ca2+ dependent manner and positively
charged dyes were uptaken in a Ca++ independent manner.
HEK-293 (rat) Patch-clamp [58] The authors showed that organic cation NMGD and the ﬂorescent dye YO-PRO
use differentmechanisms to enter the cell during prolongedATP application in
heterologously expressed rat P2X7 receptor.
Rat submandibular acinar cells Dye uptake; measurement of the production of
inositol phosphates; measurement of the
concentration of protons
[155] Propranolol inhibited the pore-forming activity of the P2X(7) receptor with-
out impairing the opening of the small cation channel coupled to this receptor.
Xenopus oocytes (mouse) Patch-clamp
Ca2+ measurements
[156] N,N-hexamethyleneamiloride (HMA) reduced the delayed component of the
BzATP-induced inﬂux ionic current. This delayed HMA-sensitive ionic current
can be carried by large organic cations, such as NMDG+. In contrast, the rap-
idly activated HMA-insensitive current is carried by Na+, Li′, and K′, but is
poorly carried by NMDG+ and Tris+.
Xenopus oocytes (rat); fresh and
cultured mice macrophages;
HEK-293 (rat)
Patch-clamp; dye uptake; assay for nitric oxide
(NO) receptor
[65] Disrupting the microtubule network with colchicine did not affect currents
generated by ATP in P2X2 and P2X7 receptor-expressing cells but inhibited up-
take of the dye Yo-Pro-1 in Xenopus oocytes and HEK-293 cells expressing these
channels. Peritoneal mouse macrophages showed less ATP-induced perme-
abilization to ethidium bromide in the presence of colchicine, and less reactive
oxygen species (ROS) formation, nitric oxide (NO) and interleukin (IL)-1b re-
lease. Colchicine treatment did not affect ATP-evoked currents in macrophages.
HEK-293 cells (human) Patch-clamp [157] HMA (5-(N,N-hexamethylene)-amiloride) was an effective antagonist at a
concentration of 10 μM.
Chinese hamster ovary cells (K1 strain) Dye uptake [158] Maitotoxin promoted ethidium bromide uptake and reduced by the calmodulin
inhibitor W7, (N-(s-aminohexyl)-5-chloro-1-naphthalenesulfonamide) but
unaffected by the ATP-P2X7 receptor antagonist oxidized ATP (adenosine 5-
triphosphate periodate oxidized sodium salt) (oATP). BzATP induced ethidium
bromide uptake and was inhibited by oATP, and unaffected by W7.
2580 L.A. Alves et al. / Biochimica et Biophysica Acta 1838 (2014) 2578–2587In Brazil, the ﬁrst studies targeting P2X7R (referred to as the P2Z re-
ceptor at that time) were conducted during the early 1990s by Albu-
querque et al. [51], who were working with polykaryon macrophagesand macrophages. They were surprised to observe that a channel
allowed the passage of molecules up to 900 kD. This work was contin-
ued by Coutinho-Silva and Persechini [27], who performed patch-
2581L.A. Alves et al. / Biochimica et Biophysica Acta 1838 (2014) 2578–2587clamp experiments in a cell-attached conﬁguration. At this time, P2X7R
was shown to be activated by ATP (at millimolar concentrations) and to
activate a high-conductance channel with a unitary conductance of ap-
proximately 400 pS in mouse macrophages; this channel was referred
to as termed a Z pore (high-conductance channel) [27,52]. These inves-
tigators demonstrated that this high-conductance channel was voltage
dependent and allowed the passage of currents mediated by large mol-
ecules, such as N-methyl-D-glucamine and glutamate. These Z pores
were found to be blocked by oxidized ATP andMg2+ and to be function-
al at temperatures above 30 °C. However, these high-conductance
channels did not appear in excised patches, providing the ﬁrst clue re-
garding the possible participation of cytoplasmic elements, such as sec-
ondmessengers and cytoskeletal proteins. Thus, to our knowledge, this
research group was the ﬁrst to propose a theory other than pore
dilation.
To date, most investigators have only reported a current of approxi-
mately 10 pS using a cell-attached conﬁguration [53]. However, some
groups have attempted to divide the macroscopic current induced by
ATP in the whole-cell conﬁguration into two distinct conductances
(or components) [54–56]. The ﬁrst component has been described as
the opening of a small channel, while the second component is related
to the high-conductance channel associated with P2X7R. However,
there is no conclusive evidence because there are no recordings of single
channels whose unitary conductance is consistent with the high-
conductance channel of this second component.
In 2005, Faria et al. [25] observed a unitary conductance of approxi-
mately 400 pS, consistent with the Z pores found in murine macro-
phages and 2BH4 cells when stimulating P2X7R with ATP or benzyl
ATP (BzATP) in a cell-attached conﬁguration. These authors observed
a linear response for positive and negative holding potentials. However,
these high-conductance channels were never observed in excised
patches, suggesting a dependence on intracellular signals, as previously
suggested by Coutinho-Silva and Persechini [27]. An interesting ﬁnding
of Faria et al. was the difference in the temperature dependence of the
2BH4 cells, in which the Z pores open below 30 °C. The unitary conduc-
tance value of pore associated with P2X7R remains controversial be-
cause other investigators have been unable to ﬁnd any channels
whose unitary conductance is consistent with the passage of molecules
up to 900 Da [57,61].
A paper published by Schachter et al. [58] described the transition
from a low-conductance channel to one with a higher conductance.
Macrophages and HEK-293 cells transfected with P2X7R were studied
using patch-clamp recordings to evaluate pore formation. High-
conductance channels were not detected in the transfected HEK-293
cells, but they were observed in mouse peritoneal macrophages. Using
dye-uptake experiments, these authors also observed a differential up-
take of cations and anions during endogenous P2X7R pore formation in
macrophages. The anionic pathways appeared to be associated with the
high-conductance channel, while the cationic pathway remained un-
identiﬁed. This channel was investigated in depth based on previous
data that reported the effect of increased intracellular Ca2+ levels and
the opening of a pore that is biophysically similar to the P2X7R pore.
Micromolar concentrations of calcium ionophores induced dye uptake
and ionic currents, resulting in a unitary conductance of 400 pS in a
cell-attached conﬁguration. Furthermore, the pore opening was unaf-
fected by P2X7R blockers, but intracellular signaling components were
modiﬁed, as was the high-conductance P2X7R channel. In addition,
this effect was not observed in excised patches. However, the element
responsible for the intracellular Ca2+-induced pore opening in mouse
macrophages and 2BH4 cells is still unknown [59].
In 2010, Yan et al. [60] performed experiments to clarify how the oc-
cupation of the three ATP-binding sites might affect P2X7R gating. They
showed that ATP concentrations in the millimolar range biphasically
activated and deactivated native receptors, whereas micromolar con-
centrations induced monophasic responses. Both phases of these re-
sponses were abolished following the addition of Az10606120, aP2X7R-speciﬁc antagonist. The slow secondary growth of the current
in the biphasic response coincided temporally with pore dilation. This
pore current was insensitive to Na+ and Ca2+ inﬂuxes, and the initial
gating properties were fully re-established after 30 min of washout.
The complex pattern of gating exhibited by wild-type channels can be
accounted for by a Markov state model that includes the negative
cooperativity of agonist binding to unsensitized receptors when one
or two binding sites are occupied; when two sites are bound, the chan-
nel pore opens to a low-conductance state. When three sites are occu-
pied, a high-conductance state (pore dilation) is triggered. In contrast,
Flittiger et al. [61] investigated the participation of protons in the activa-
tion of human P2X7Rs (hP2X7Rs). They observed that hP2X7R
expressed in Xenopus laevis oocytes was activated by ATP or BzATP at
different pH levels.While the unitary currents were found to be blocked
by protonation, the high-conductance channel was not recorded.
Recently, Roger et al. [62] characterized the functional properties of
the inward current activated by ATP in human and rat P2X7Rs thatwere
transiently expressed inHEK-293 cells. They found that this currentwas
facilitated in humans, and it was independent of Ca2+/calmodulin. In
contrast, in rats, the current was Ca2+/calmodulin dependent. Some
authors suggest that the second component of this inward current is re-
sponsible for pore formation (high-conductance channel) [60,62,63].
Two recent papers have usedmutations to test the pore dilation the-
ory; however, the results are not deﬁnitive, as the authors noted in the
discussion sections of their papers. Sun and co-workers showed that the
second transmembrane domain is necessary for pore formation because
the dye uptake was reduced when the second transmembrane domain
of P2X7R was replaced by the second transmembrane domain of
P2X1R [64]. However, the surface expressionwas also reduced, suggest-
ing that this reduction could be due to the decreased presence of the re-
ceptor at the membrane. In the other paper, Browne also proposed the
direct involvement of the second transmembrane domain of P2X7R
in the permeation pathway for high-molecular-weight dyes [42].
Using mutations in the second transmembrane domain and cysteine-
accessibility experiments, the researchers showed that the mutant re-
ceptor could form (at least part of) the non-selective pore of P2X7R.
Nevertheless, the previously mentioned issue of surface expression
and reduced dye uptake could have affected the results. Moreover, the
data require a more careful analysis. The dye-uptake curves appeared
to be identical within the standard deviation. Similarly, we cannot dis-
cern a clear difference between the currents from the T348C mutant
and the currents from the wild-type receptor in the presence of large
methanethiosulfonate reagents. Thus, the entity responsible for the for-
mation of the large pore remainsunidentiﬁeddespite the elegant exper-
iments performed in these two papers.
5. Are other high-conductance channels associated with P2X7R?
Asmentioned previously, there are some discrepancies in the litera-
ture regarding the high-conductance channel associated with P2X7R.
The disagreements among several laboratories (see Table 1) regarding
P2X7R pore formation (high-conductance channel) raise the following
question: is there a single entity responsible for the P2X7R pore? The
published data suggest the existence of more than one pore-formation
mechanism, depending on the cell type, species or mode of cellular ma-
nipulation (for example, transfection) [58,65,66]. In addition, P2X7R
may act through multiple “pore proteins” at the same time [67]. Our
group [59] showed that calcium ionophores could greatly increase in-
tracellular Ca2+ levels and induce dye uptake. Furthermore, we studied
a pore with biophysical and pharmacological characteristics similar to
the P2X7R pore. In addition, maitotoxin, which also triggers substantial
intracellular Ca2+ entry, has been shown to induce pore opening and to
enable the uptake of ﬂuorescent dyes similarly to the P2XR pore [68].
Likewise, Cankurtaran-Sayar et al. recently demonstrated that RAW
264.7 cells andHEK-293 cells transfectedwith rat P2X7R take up cation-
ic (propidium iodide, PI) and anionic (Lucifer yellow, LY) ﬂuorescent
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cells exhibit a pathway that is permeable to cationic dyes in a Ca2+-
independent manner, while another pathway is permeable to anionic
dyes in a Ca2+-dependentmanner. In contrast, RAW264.7 cells are per-
meable to both dyes, and intracellular Ca2+ chelation only slightly re-
duces the effect induced by ATP. However, the addition of an
extracellular saline solution without Ca2+ reduces LY uptake without
interfering with PI uptake. Taken together, these results suggest the
possibility that different channels are involved in P2X7R pore formation
(high-conductance channel). We hypothesized that these other high-
conductance channels may contribute to P2X7R pore formation in
certain conditions depending on various factors, including the level of
endogenous expression in a particular cell type, the species or the acti-
vation of the intracellular signaling pathways that regulate these chan-
nels. Moreover, there are several candidates for channels that allow the
passage of low-molecular-weight dyes, such as LY and YO-PRO-1,
through the formation of high-conductance channels whose conduc-
tances are generally greater than 200 pS and whose pore diameters
range from 8 to 40 Å [7,25,59]. In mammalian cells, these candidates
are the connexin hemichannels (Cx43 and Cx32), the pannexins
(pannexin-1), the maxi-anion channel, the voltage-dependent anionic
channel (VDAC), themaxi-K channel, themaitotoxin pore, the transient
receptor potential vanilloid type-1 (TRPV1) pore, the transient receptor
potential ankyrin type-1 (TRPA1) pore, the ATP-activated P2X pores
(P2X2, P2X4 and P2X7R) and the calcium homeostasis modulator 1
(CALHM1) pore. The general characteristics of these channels are sum-
marized in Table 2 and illustrated in Fig. 1. In addition, it is a well-
established fact that the activation of P2X7R causes cellular swelling
[69], a common event that activates most of the channels mentioned
above [70–72]. This second possibility is illustrated in Fig. 2. At pharma-
cological concentrations (millimolar levels) in vitro, ATP can activate
P2X7R, causing cellular swelling that can open the channel, as shown
in Fig. 2. This process can initiate a positive feedback loop, increasing
ATP secretion [152] as well as the intracellular passage of high-
molecular-weight dyes from the extracellular side. Other researchers
in the P2X7R ﬁeld have also begun to notice the potential participation
of other channels as conduits for dyes such as Yo-Pro-1, LY andPI [59,66,
67,73,74].
6. Therapeutic potential of agonists and antagonists of P2X7R in
different diseases
Since the seminal paper by Burnstock in 1972 [3] that established
the class of purinergic receptors, only one medication, a P2Y12R antag-
onist, has been approved for clinical use, and thismedication has shown
great success at lowering the death rate associated with acute coronary
syndrome [82]. Currently, this compound is third-generation acting
through inhibition of platelet aggregation. For P2X7R, no such com-
pound is used in clinical practice. Nevertheless, there are several
phase I and II clinical trials aimed at evaluating the efﬁcacy of P2X7R
antagonists in treating various diseases, including chronic pulmonary
conditions, rheumatoid arthritis and inﬂammatory bowel diseases
(reviewed by Arulkumaran) [83]. Further research on P2X7R and its
actions may reveal novel therapeutic targets for combating neurode-
generative conditions, and pre-clinical studies indicate that P2X7R an-
tagonists may be used to treat neuro-inﬂammatory diseases, such as
stroke, brain trauma, amyotrophic lateral sclerosis and multiple sclero-
sis. In initial studies, P2X7R knockout mice showed no general damage
from excitotoxic or ischemic insults compared with wild-type mice
[84] but did show decreased inﬂammatory and neuropathic pain with
unaltered, normal nociception [11,85]. More recent data suggest an im-
portant role for P2X7R in calcium-dependent microglial cell death in-
duced by stroke-like conditions during oxygen–glucose deprivation
[86].
The inhibition of ATP receptors (P2X7R or P2X4R), downstream sig-
naling pathways, chemokines and proinﬂammatory cytokines should
Fig. 1. Cellular swelling after P2X7R activation at pharmacological concentrations (millimolar range) of ATP. This scheme shows channels that are opened by cellular swelling. Some chan-
nels, such as maxi-anion channels, are selective for anions; TRPR-V1 is selective for cations, and connexins and pannexins show low selectivity.
2583L.A. Alves et al. / Biochimica et Biophysica Acta 1838 (2014) 2578–2587contribute to novel therapies for chronic pain [87,88]. Microglial P2X7R
and its downstream signaling pathways play a pivotal role in the induc-
tion of spinal long-term potentiation (LTP) and persistent pain [89]. It
has been shown that P2X7R has a role in the onset and persistence of
neuropathic pain and that spinal P2X7R mediates microglia activation
[90].Fig. 2. Signaling pathways of high-conductance channels. This scheme shows the intracellular pa
pharmacological or functional properties of the P2X7R-associated pore. The scheme illustrates t
levels (2); themaitotoxin-induced pore (3); themaxi-anion channel (4); connexin and pannex
pore (6).A commonality among all of these diseases is an inﬂammatory com-
ponent. In this regard, P2X7R is a key element because it activates
the inﬂammasome, a multiprotein oligomeric complex composed
of NALP3 (a type of NOD-like receptor), caspase 1 and apoptosis-
associated speck-like protein containing a carboxy-terminal caspase
activation and recruitment domain (CARD) (ASC, an adaptor protein),thways related to regulation of the high-conductance channels alongwith the biophysical,
he following types of channels: TRPV (1); the pore induced by increased intracellular Ca2+
in-1 hemichannels or the calcium homeostasismodulator 1 (CALHM1) (5); and the TRPA1
2584 L.A. Alves et al. / Biochimica et Biophysica Acta 1838 (2014) 2578–2587in associationwith other signaling pathways. These components are key
players in the release or regulation of several pro-inﬂammatory media-
tors, including interleukin-1 (IL-1)-beta, IL-8, tumor necrosis factor
(TNF)-α, nitric oxide (NO) and reactive oxygen species (ROS) [91].
Thus, P2X7R antagonists have become a pharmacological target for sev-
eral pharmaceutical companies. Recently, several groups have provided
evidence that P2X7R antagonists could be used to treat gouty arthritis.
In support of this idea, the inﬂammasome activation by uric acid parti-
cles has been shown to depend on P2X7R activation [92]. Furthermore,
it has been demonstrated that colchicine may also act through P2X7R
inhibition [65]. An elegant discussion of this hypothesis for a P2X7R-
based treatment of gouty arthritis has been published by Tao and co-
workers [93].
The role of P2X7R in transplantation has also been studied; pre-
clinical studies with mice and human samples have revealed that an
antagonist of P2X7R, oxidized ATP, increases islet cell and heart trans-
plantation survival. These studies have demonstrated an upregulation
of P2X7R expression in graft-inﬁltrating T cells [94,95].
Cancer also provides a possible target for P2X7R agonists (or in some
cases, antagonists) [99]. Several types of tumor cells express high levels
of P2X7R [96,97]. There has been some debate regarding whether
P2X7R activation would induce apoptosis in cancer cells or behave as
a growth factor [75,98,100]. As suggested byDi Virgilio, this discrepancy
could be related to the ATP concentration used, i.e., a low concentration
might induce cellular growth, while high concentrations (mM range)
would induce cellular death [97]. Indeed, P2X7R expression has been
correlated with the progression of glioma and particularly with resis-
tance to ATP-induced cell death. Human U-138MG and U-251MG glio-
ma cells have been shown to be resistant to death when treated with
either ATP (5 mM) or BzATP (100 μM), whereas the cell viability of ra-
diosensitiveM059J glioma cells signiﬁcantly decreases under these con-
ditions [100]. In addition, stimulation of P2X7R can increase the antigen
presentation and secretion of IL-1-beta by dendritic cells; this result
suggests a role for P2X7R in the immune response against tumor cells
[101]. A link has also been demonstrated between statins, cholesterol-
lowering drugs and cancer protection in different types of cells (lung,
pancreatic and prostatic). Statins, or extracellular ATP, induce a complex
response in insulin-stimulated A549 cells, leading to depletion of nucle-
ar pAkt [102]. Recently, extracellular ATP-induced invasive growth in
PTEN-positive cells was counteracted by statins via P2X7R [103]. This
work reported that P2X7 signaling involves Eps15 homology (EH)
domain-binding protein 1 (EHBP1), which has previously been shown
to be associated with aggressive prostate cancer and insulin-
stimulated trafﬁcking and cell migration. A complex is formed between
EHBP1 and P-Rex1, a guanine nucleotide exchange factor, and this com-
plex is involved in the anti-invasive effect of atorvastatin [103]; thus, the
study showed that statins decrease the levels of phosphorylated Akt.
Another possible target for P2X7R agonists is tuberculosis (TB), which
is a chronic infectious condition caused byMycobacterium tuberculosis
(MTB), an intracellular pathogen. This disease constitutes a global
health problem, and it is estimated that one-third of the world's popu-
lation is infected with MTB. Only approximately 5–10% of infected indi-
viduals will develop the clinical disease [104,105]. Macrophages act as
the major host cells for intracellular mycobacterial replication and are
also responsible for regulating the growth and viability of this pathogen
[106]. In 1997, Lammas et al. showed that ATP could induce the killing of
mycobacteria by humanmacrophages, suggesting that the P2X7R path-
way might mediate the control of M. tuberculosis infection in humans
[107]. Since the publication of that milestone paper, several groups
have shown that P2X7R activation induces apoptosis and that infected
macrophages interfere with certain MTB escape mechanisms, leading
to mycobacterial death [112]. In addition, several polymorphisms in
P2X7R have been associated with tuberculosis in various ethnic groups
[108]. A recent meta-analysis found that 1513A/C mutations in P2X7R
are associated with increased susceptibility to tuberculosis [111]. Thus,
ATP agonists may function as chemotherapeutic drugs in associationwith the common antibiotics used to treat tuberculosis. Other intracel-
lular pathogensmight also be potential targets for P2X7R agonists [100].
One possibility that appears to have been overlooked bypharmaceu-
tical companies is the potential for drug delivery using the high-
conductance channel of P2X7R to increase the passage of hydrophilic
drugs into the cytoplasm of cells expressing the P2X7R pore. Thus, the
generation of a P2X7R agonist that would selectively stimulate the
high-conductance channel and not the other signaling pathways associ-
ated with this receptor could lead to beneﬁcial results. Indeed, different
structural ligands for many speciﬁc G protein-coupled receptors are
able to bind to different conformational states that are responsible for
the differential activation of signaling cascades [113].
7. Concluding remarks
Since the ﬁrst formal deﬁnition of P2X7R as an ATP receptor in mast
cells by Cockcroft and Gomperts [49], several articles have been pub-
lished on the role of P2X7R in different cell types in an attempt to eluci-
date the mechanisms associated with the high-conductance channel
(pore) that is responsible for the passage of dyes. Evidence has been
presented that supports two distinct theories of pore formation, leading
to disagreements among several laboratories. The divergence of these
ﬁndings may be related to the differences in the particular cell type
studied and/or the different signaling mechanisms associated with
pore formation. The activation of other channels with the same cut-off
as the P2X7R-associated pore should also be considered, as illustrated
in Table 1. Despite the great efforts exerted in this exciting research
area, the pore-formation mechanism continues to be an enigmatic phe-
nomenon that must be deciphered to permit the rational use and syn-
thesis of novel agonists and antagonists of P2X7R.
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